News >

Molecular Markers Critical to Guiding Treatment in Newly Diagnosed mCRC

Jessica Hergert
Published: Monday, Feb 17, 2020

Andrea Cercek, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center

Andrea Cercek, MD

The advent of immunotherapy and targeted agents, as well as understanding the impact of tumor sidedness, have impacted treatment decisions for newly diagnosed patients with metastatic colorectal cancer (mCRC), explained Andrea Cercek, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication